<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162628</url>
  </required_header>
  <id_info>
    <org_study_id>SU019</org_study_id>
    <nct_id>NCT02162628</nct_id>
  </id_info>
  <brief_title>Exair® Versus Native Tissue Repair for Prolapse</brief_title>
  <official_title>Exair® Prolapse Repair System Versus Native Tissue Repair for Treatment of Pelvic Organ Prolapse, Exair 522 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare safety and effectiveness of the Exair Prolapse Repair
      System for treatment of pelvic organ prolapse to traditional native tissue repair through 36
      months of follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Device voluntarily withdrawn from commercial use by manufacturer
  </why_stopped>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of Prolapse</measure>
    <time_frame>36 Month</time_frame>
    <description>Recurrent prolapse is measured anatomically at the target compartment by leading edge of prolapse beyond the hymenal ring by POP-Q examination, or additional surgical treatment for pelvic organ prolapse in the target vaginal compartment(s), or patient reporting symptoms of vaginal bulging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events</measure>
    <time_frame>36 Month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of prolapse</measure>
    <time_frame>36 Month</time_frame>
    <description>Recurrent prolapse is measured anatomically by leading edge of prolapse in the target compartment at or beyond the hymenal ring by POP-Q examination, or additional surgical treatment for pelvic organ prolapse in the target vaginal compartment(s), or patient reporting symptoms of vaginal bulging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of other adverse events</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Quality of Life scores for PFDI-20, PISQ-12, and PFIQ-7</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Subjects experiencing vaginal bulge</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rates of revision and/or re-surgery</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">79</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>Exair for Total Repair</arm_group_label>
    <description>Total repair with Exair Prolapse Repair System alone or in combination with native tissue repair</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total Native Tissue Repair</arm_group_label>
    <description>Total repair with native tissue only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Exair Prolapse Repair System</intervention_name>
    <arm_group_label>Exair for Total Repair</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Native Tissue Repair</intervention_name>
    <arm_group_label>Total Native Tissue Repair</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult female patients with pelvic organ prolapse who are candidates for transvaginal
        surgical repair.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female at least 18 years of age

          -  Subject has pelvic organ prolapse with leading edge at or beyond the hymen. At or
             beyond the hymen is defined as POP-Q scores of Ba ≥0 and Bp ≥0 and C≥ -1/2 tvl

          -  Subject reports a bothersome bulge they can see or feel per PFDI-20 question 3,
             response of 2 or higher (i.e. responses of &quot;somewhat&quot;, &quot;moderately&quot; or &quot;quite a bit&quot;)

          -  Subject is willing to provide written informed consent

          -  Subject is willing and able to comply with the follow-up regimen

        Exclusion Criteria:

          -  Subject is pregnant or intends to become pregnant during the study

          -  Subject has an active or chronic systemic infection including any gynecologic
             infection, untreated urinary tract infection (UTI), or tissue necrosis

          -  Subject has a history of pelvic organ cancer (e.g. uterine, ovarian, bladder, or
             cervical)

          -  Subject has had prior or is currently undergoing radiation, laser therapy, or
             chemotherapy in the pelvic area

          -  Subject has taken systemic steroids (within the last month), or immunosuppressive or
             immunomodulatory treatment (within the last 3 months)

          -  Subject has a systemic connective tissue disease (e.g. scleroderma, systemic lupus
             erythematosus (SLE), Marfan syndrome, Ehlers Danlos, collagenosis, polymyositis or
             polymyalgia rheumatica)

          -  Subject has chronic systemic pain that includes the pelvic area or chronic focal pain
             that involves the pelvis

          -  Subject has uncontrolled diabetes mellitus (DM)

          -  Subject has a known neurologic or medical condition affecting bladder function (e.g.
             multiple sclerosis, spinal cord injury, or stroke with residual neurologic deficit)

          -  Subject is seeking obliterative vaginal surgery as treatment for pelvic organ prolapse
             (colpocleisis)

          -  Subject is not able to conform to the modified dorsal lithotomy position

          -  Subject is currently participating in or plans to participate in another device or
             drug study during this study

          -  Subject has a known sensitivity to polypropylene

          -  Subject has had previous prolapse repair with mesh in the target compartment(s)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Lukban, DO, FACOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Pelvic Solutions Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Progressive GYN Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Advantage</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Urogynecology of Michigan</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Women's Care</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Urogynecology Associates</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Urogynecology</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Health Services</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute for Female Pelvic Medicine and Reconstructive Surgery</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Urogynecology Associates, P.C.</name>
      <address>
        <city>Williston</city>
        <state>Vermont</state>
        <zip>05495</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carillion Clinic OB/GYN</name>
      <address>
        <city>Christiansburg</city>
        <state>Virginia</state>
        <zip>24073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS-CRC</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <last_update_submitted>December 11, 2015</last_update_submitted>
  <last_update_submitted_qc>December 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pelvic Floor Disorder</keyword>
  <keyword>Pelvic Organ Prolapse</keyword>
  <keyword>Sexual Dysfunction</keyword>
  <keyword>Mesh</keyword>
  <keyword>POP</keyword>
  <keyword>Transvaginal</keyword>
  <keyword>Total Repair</keyword>
  <keyword>Uterine Prolapse</keyword>
  <keyword>Cystocele</keyword>
  <keyword>Rectocele</keyword>
  <keyword>Enterocele</keyword>
  <keyword>Vaginal Vault Prolapse</keyword>
  <keyword>Native Tissue Repair</keyword>
  <keyword>Repair Augmented with Mesh</keyword>
  <keyword>Pathological Conditions, Anatomical</keyword>
  <keyword>Exair Prolapse Repair System</keyword>
  <keyword>Vaginal Mesh</keyword>
  <keyword>Transvaginal Mesh</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

